Graduation study design: Evaluation of once‐weekly subcutaneous administration of gantenerumab on brain amyloid load

Background Gantenerumab, a human monoclonal antibody targeting aggregated beta‐amyloid (Aβ), is a potential disease‐modifying treatment for early Alzheimer’s disease (AD). Exposure‐dependent signals of clinical efficacy were observed with low‐dose gantenerumab in post‐hoc analyses of the SCarlet RoA...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Alzheimer's & dementia 2021-12, Vol.17 (S9), p.n/a
Hauptverfasser: Boess, Frank, Sakaoka, Shunsuke, Abi‐Saab, Danielle, Scelsi, Marzia Antonella, Delmar, Paul, Hofmann, Carsten, Klein, Gregory, Baudler, Monika, Doody, Rachelle, Kerchner, Geoffrey A
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!